Exclusive: Change Healthcare cyber attack outage could last weeks

That timeline, while vague, still provides more clarity than UnitedHealth has offered publicly since the outage began Feb. 21.

February 29, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Change Healthcare cyber attack outage could persist for weeks, UnitedHealth Group executive suggests Payment processor for UnitedHealth Group will be offline for weeks. Temporary payment system, loan program offered to ease cash flow problems for providers. By Brittany Trang STAT+ | A 'vaccine-like' version of Wegovy is on the drawing board at Novo Nordisk Novo Nordisk wants to develop obesity drugs with longer-lasting weight loss effects than existing treatments Wegovy and Zepbound. By Elaine Chen STAT+ | What does America's crackdown on Chinese firms mean for the U.S. biotech sector? Chinese biotechs targeted in proposed Biosecure Act do billions in business with U.S. drugmakers. Lobbyists say move to protect genetic data could backfire. By John Wilkerson Giannis Papanikos/AP STAT+ | Pfizer is about to make a big push in cancer. Will investors listen? In an interview, CEO Albert Bourla was insistent that investors are missing the potential of Pfizer's acquisition of Seagen. By Matthew Herper STAT+ | This chemist's last startup sold for $4 billion. Now investors have poured $173 million into her next act Jean Cui's new company is preparing to start clinical studies of potential medicines that could someday treat blood cancer and lung cancer. By Matthew Herper Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 In this episode, we discuss a banner month for biotech stocks and the latest twist in obesity research. By Damian Garde and Allison DeAngelis and Adam Feuerstein Molly Ferguson/STAT STAT+ | An inside look at PIPEs, the financing trend that has biotech abuzz This year has seen at least 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds). By Adam Feuerstein RSV vaccines may be linked to small increased risk of developing Guillain-Barré syndrome, data suggest Experts cautioned it's too early to determine if there is a true increased risk of developing Guillain-Barré syndrome after RSV vaccination. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser